中药联合阿奇霉素序贯治疗儿童支原体肺炎的疗效与安全性:随机对照试验的Meta分析
该Meta分析纳入51项RCT、5799例1-14岁儿童,评估中药联合阿奇霉素序贯治疗儿童支原体肺炎。结果显示联合治疗可提高治愈率(OR=2.34)和有效率(OR=5.21),缩短咳嗽、发热及肺部啰音消失时间,改善CRP、IL-6、TNF-α水平,并减少不良反应(OR=0.37)。结论认为该方案疗效与安全性较好。
要点
- 中药联合阿奇霉素可提高儿童支原体肺炎治愈率(OR=2.34)和有效率(OR=5.21)。
- 联合治疗缩短咳嗽、发热、肺部啰音消失时间,并降低CRP、IL-6、TNF-α。
- 联合治疗不良反应更少(OR=0.37),安全性较好。
核心结论
- 中药联合阿奇霉素序贯治疗儿童支原体肺炎具有较好的临床疗效和安全性。
主要发现
- 治愈率OR=2.34(95%CI:2.06至2.64),有效率OR=5.21(95%CI:4.22至6.43)。
- 咳嗽消失时间WMD=-1.62(95%CI:-1.90至-1.34),发热持续时间WMD=-1.62(95%CI:-1.96至-1.29),肺部啰音消失时间WMD=-1.15(95%CI:-1.32至-0.98)。
- CRP水平WMD=-2.06(95%CI:-2.57至-1.55),IL-6水平WMD=-1.92(95%CI:-2.51至-1.34),TNF-α水平WMD=-1.59(95%CI:-2.14至-1.04)。
- 不良反应OR=0.37(95%CI:0.32至0.44)。
临床怎么用
- 在儿童支原体肺炎治疗中,可考虑中药联合阿奇霉素序贯方案以改善症状和炎症指标,并关注不良反应减少的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional Chinese medicine (TCM) is used to treat mycoplasma pneumonia (MP) in children with favorable treatment outcome in China. In the present study, we evaluated the clinical efficacy of TCM combined with azithromycin (AZM) for the treatment of MP among children, providing high evidence-based reference for clinical treatment. METHOD: We retrieved eligible randomized controlled trials (RCTs) from CQVIP, CNKI, WanFang, NSTL, PubMed, Embase, and Embase databases from January 2000 to November 2023. Data extraction and quality assessment of the enrolled studies were independently by two reviewers. Review Manager 5.3 was used for meta-analysis. RESULT: A total of 51 RCTs involving 5,799 children aged 1-14 enrolled. Meta-analysis demonstrated that TCM combined with AZM improved the cure rate (odds ratio [OR] = 2.34, 95% CI: 2.06 to 2.64) and the effective rate (OR = 5.21, 95% CI: 4.22 to 6.43), shorted the disappearance duration of cough (WMD = -1.62, 95% CI: -1.90 to -1.34), the duration of fever (WMD = -1.62, 95% CI: -1.96 to -1.29), and the disappearance time of lung rales (WMD = -1.15, 95% CI: -1.32 to -0.98), improved CRP levels (WMD = -2.06, 95% CI: -2.57 to -1.55), IL-6 levels (WMD = -1.92,95% CI: -2.51 to -1.34), and TNF-α levels (WMD = -1.59, 95% CI: -2.14 to -1.04), and reduced adverse reactions (OR = 0.37, 95% CI: 0.32 to 0.44). CONCLUSION: TCM combined with AZM in the treatment of MP among children has favorable clinical efficacy and safety.
引用
- Lyu J, Fan F, Li J, et al. Efficacy and safety of traditional Chinese medicine combined with azithromycin sequential therapy for mycoplasma pneumonia among children: a meta-analysis of randomized controlled trials. Front Pharmacol. 2024. PMID: 39484158. doi:10.3389/fphar.2024.1431706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。